At the same time, we recognize that there are potential limitations when targeting LRRK2 and GBA, even in PD patients who carry the genetic risk variants, most notably because we do not know in which temporal phase of the disease are the LRRK2- and GBA-related pathways important when conveying elevated PD risk. Here, LRRK2 is linked to Parkinson disease.